Goldman: Sell This Biotech Stock Now

Short sellers have been in the driver's seat on ACOR stock

Dec 11, 2018 at 11:33 AM
facebook X logo linkedin


The shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are spiraling today, after Goldman Sachs downgraded the drug stock to "sell" from "neutral," and nearly halved its price target to $10 from $19 -- a roughly 50% discount to last night's close, and the lowest target on Wall Street. The brokerage firm expects Ampyra revenue to ease as generics for the multiple sclerosis drug hit the market, and sees lower-than-anticipated U.S. sales for ACOR's Parkinson's drug, Inbrija.

At last check, ACOR is trading down 15.1% at $16.16, set for its worst day since Sept. 10 -- when news of a regulatory hurdle for Inbrija sent the shares tumbling more than 24%. The security has now sliced through recent support in the $17 region, home to its negative 20% year-to-date return, and is closing in on its Sept. 13 annual low of $15.60.

acor stock daily chart on dec 11

Against this backdrop, it's not hard to see why most analysts are already bearish on Acorda Therapeutics. However, two of eight brokerages still maintain a "strong buy" rating on the stock, and the average 12-month price target sits all the way up at $22.11 -- suggesting more negative analyst notes could come down the pike.

Elsewhere, short sellers have been actively targeting ACOR stock, which has likely increased pressure on the shares. Short interest is up 88.5% from the Sept. 1 reporting period to 8.03 million shares -- the most in over a year. These bearish bets accounts for 17.2% of the equity's available float, or 11.5 times the average pace of trading. Shorts are sidelined at the moment, though, with Acorda Therapeutics short-sale restricted during today's bear gap.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI